S. Lu

发表

Predictors of asthma following severe respiratory syncytial virus (RSV) bronchiolitis in early childhood

T. Hartert, T. Reiss, M. Everard, 2016, Pediatric pulmonology.

Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.

A. Mosholder, K. Phelan, Susan Lu, 2003, The Journal of clinical psychiatry.

CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.

E. R. Sutherland, H. Magnussen, H. Watz, 2015, American journal of respiratory and critical care medicine.

Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall.

M. Malice, T. Reiss, G. Philip, 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Clinical efficacy of montelukast in adults and children

T. Reiss, B. Knorr, G. Noonan, 2001 .

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.

D. Bernstein, F. Horak, H. Nelson, 2015, The Journal of allergy and clinical immunology.

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.

D. Bernstein, H. Nelson, H. Nolte, 2016, The Journal of allergy and clinical immunology.

Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet.

D. Bernstein, H. Nelson, H. Nolte, 2018, The journal of allergy and clinical immunology. In practice.

Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma

D. Bernstein, H. Nelson, H. Nolte, 2017, Postgraduate medicine.

Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets.

T. Casale, R. Lockey, H. Nelson, 2017, The journal of allergy and clinical immunology. In practice.

Quality assurance of asthma clinical trials.

P. Enright, T. Reiss, Susan Lu, 2002, Controlled clinical trials.

Pharmacokinetics and Safety of Montelukast Oral Granules in Children 1 to 3 Months of Age With Bronchiolitis

G. Kearns, T. Reiss, L. Maganti, 2008, Journal of clinical pharmacology.

Clinical Studies of Combination Montelukast and Loratadine in Patients with Seasonal Allergic Rhinitis

M. Malice, T. Reiss, Susan Lu, 2009, The Journal of asthma : official journal of the Association for the Care of Asthma.

Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial.

D. Bernstein, H. Nelson, H. Nolte, 2020, The journal of allergy and clinical immunology. In practice.

SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.

D. Bernstein, H. Nelson, H. Nolte, 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial

N. Noulin, Susan Lu, M. Kitt, 2022, Pulmonary Therapy.

The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough

P. Reyfman, L. McGarvey, Wen-Chi Wu, 2023, Lung.

Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008

G. D. Dal Pan, T. Hammad, Esther H Zhou, 2010, Pharmacoepidemiology and drug safety.

Effect of montelukast for treatment of asthma in cigarette smokers.

Todor A Popov, D. Price, P. Polos, 2013, The Journal of allergy and clinical immunology.

Efficacy and Safety of the SQ-House Dust Mite Sublingual Immunotherapy Tablet in North American Children and Adults: Findings from a Large Randomized, Placebo-Controlled Clinical Trial

D. Bernstein, H. Nelson, H. Nolte, 2016 .

Treatment with the SQ house dust mite sublingual immunotherapy tablet may be initiated year-round.

D. Bernstein, H. Nolte, J. Kleine‐Tebbe, 2018, The journal of allergy and clinical immunology. In practice.

Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.

D. Bernstein, H. Nolte, S. Gawchik, 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Topiramate-associated secondary angle-closure glaucoma: a case series.

P. Nourjah, W. Chambers, J. Beitz, 2002, Archives of ophthalmology.